Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 711-720 of 982 for hematology

Edit search filters
  1. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

    Rochester, MN

  2. Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

  3. Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

    Rochester, MN

  8. A Study to Evaluate Itacitinib for Low Risk Graft-vs-Host Disease (GVHD)

    Rochester, MN

  9. Study of Efficacy and Safety of CTL019 in Adult ALL Patients

    Scottsdale/Phoenix, AZ

  10. A Study to Evaluate 9-ING-41 As a Single Agent or in Combination with Ruxolitinib in Myelofibrosis Patients

    Rochester, MN

.

Mayo Clinic Footer